Evaluation of Immune‐enhancing Effects of Ibuprofen in an Immunodeficiency Model

Joseph L. Jorizzo, Randall M. Goldblum, Jerry C. Daniels, Yukinobu Ichikawa, Marlyn P. Langford, Karis M. Fagan

Research output: Contribution to journalArticle

Abstract

Abstract: Three children and one adult with chronic mucocutaneous candidosis with documented deficient cellular immunity to Candida antigen were evaluated as a model to study the specific cellular immune‐enhancing potential of the prostaglandin synthetase inhibitor ibuprofen. Oral ibuprofen failed to have any consistent effect during sequential 4‐week on and off cycles on the following parameters: delayed hypersensitivity skin testing; lymphocyte transformation to Candida antigen; T‐cell subsets as determined by monoclonal antibody techniques; production of human immune interferon in response to staphylococcal enterotoxin A (SEA). Two patients showed a trend toward enhanced lymphocyte transformation to PHA while taking ibuprofen. In two patients who were studied 8–10 weeks after discontinuation of oral ketoconazole therapy, clinical recurrence of CMC was not prevented by oral ibuproten therapy.

Original languageEnglish (US)
Pages (from-to)183-187
Number of pages5
JournalInternational Journal of Dermatology
Volume24
Issue number1
DOIs
StatePublished - 1985

Fingerprint

Ibuprofen
Lymphocyte Activation
Candida
Chronic Mucocutaneous Candidiasis
Antigens
Prostaglandin Antagonists
Ketoconazole
Delayed Hypersensitivity
Prostaglandin-Endoperoxide Synthases
Cellular Immunity
Interferon-gamma
Monoclonal Antibodies
Recurrence
Skin
Therapeutics

ASJC Scopus subject areas

  • Dermatology

Cite this

Jorizzo, J. L., Goldblum, R. M., Daniels, J. C., Ichikawa, Y., Langford, M. P., & Fagan, K. M. (1985). Evaluation of Immune‐enhancing Effects of Ibuprofen in an Immunodeficiency Model. International Journal of Dermatology, 24(1), 183-187. https://doi.org/10.1111/j.1365-4362.1985.tb05423.x

Evaluation of Immune‐enhancing Effects of Ibuprofen in an Immunodeficiency Model. / Jorizzo, Joseph L.; Goldblum, Randall M.; Daniels, Jerry C.; Ichikawa, Yukinobu; Langford, Marlyn P.; Fagan, Karis M.

In: International Journal of Dermatology, Vol. 24, No. 1, 1985, p. 183-187.

Research output: Contribution to journalArticle

Jorizzo, JL, Goldblum, RM, Daniels, JC, Ichikawa, Y, Langford, MP & Fagan, KM 1985, 'Evaluation of Immune‐enhancing Effects of Ibuprofen in an Immunodeficiency Model', International Journal of Dermatology, vol. 24, no. 1, pp. 183-187. https://doi.org/10.1111/j.1365-4362.1985.tb05423.x
Jorizzo, Joseph L. ; Goldblum, Randall M. ; Daniels, Jerry C. ; Ichikawa, Yukinobu ; Langford, Marlyn P. ; Fagan, Karis M. / Evaluation of Immune‐enhancing Effects of Ibuprofen in an Immunodeficiency Model. In: International Journal of Dermatology. 1985 ; Vol. 24, No. 1. pp. 183-187.
@article{adf6017a8ec143e7834ee442b345e29b,
title = "Evaluation of Immune‐enhancing Effects of Ibuprofen in an Immunodeficiency Model",
abstract = "Abstract: Three children and one adult with chronic mucocutaneous candidosis with documented deficient cellular immunity to Candida antigen were evaluated as a model to study the specific cellular immune‐enhancing potential of the prostaglandin synthetase inhibitor ibuprofen. Oral ibuprofen failed to have any consistent effect during sequential 4‐week on and off cycles on the following parameters: delayed hypersensitivity skin testing; lymphocyte transformation to Candida antigen; T‐cell subsets as determined by monoclonal antibody techniques; production of human immune interferon in response to staphylococcal enterotoxin A (SEA). Two patients showed a trend toward enhanced lymphocyte transformation to PHA while taking ibuprofen. In two patients who were studied 8–10 weeks after discontinuation of oral ketoconazole therapy, clinical recurrence of CMC was not prevented by oral ibuproten therapy.",
author = "Jorizzo, {Joseph L.} and Goldblum, {Randall M.} and Daniels, {Jerry C.} and Yukinobu Ichikawa and Langford, {Marlyn P.} and Fagan, {Karis M.}",
year = "1985",
doi = "10.1111/j.1365-4362.1985.tb05423.x",
language = "English (US)",
volume = "24",
pages = "183--187",
journal = "International Journal of Dermatology",
issn = "0011-9059",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Evaluation of Immune‐enhancing Effects of Ibuprofen in an Immunodeficiency Model

AU - Jorizzo, Joseph L.

AU - Goldblum, Randall M.

AU - Daniels, Jerry C.

AU - Ichikawa, Yukinobu

AU - Langford, Marlyn P.

AU - Fagan, Karis M.

PY - 1985

Y1 - 1985

N2 - Abstract: Three children and one adult with chronic mucocutaneous candidosis with documented deficient cellular immunity to Candida antigen were evaluated as a model to study the specific cellular immune‐enhancing potential of the prostaglandin synthetase inhibitor ibuprofen. Oral ibuprofen failed to have any consistent effect during sequential 4‐week on and off cycles on the following parameters: delayed hypersensitivity skin testing; lymphocyte transformation to Candida antigen; T‐cell subsets as determined by monoclonal antibody techniques; production of human immune interferon in response to staphylococcal enterotoxin A (SEA). Two patients showed a trend toward enhanced lymphocyte transformation to PHA while taking ibuprofen. In two patients who were studied 8–10 weeks after discontinuation of oral ketoconazole therapy, clinical recurrence of CMC was not prevented by oral ibuproten therapy.

AB - Abstract: Three children and one adult with chronic mucocutaneous candidosis with documented deficient cellular immunity to Candida antigen were evaluated as a model to study the specific cellular immune‐enhancing potential of the prostaglandin synthetase inhibitor ibuprofen. Oral ibuprofen failed to have any consistent effect during sequential 4‐week on and off cycles on the following parameters: delayed hypersensitivity skin testing; lymphocyte transformation to Candida antigen; T‐cell subsets as determined by monoclonal antibody techniques; production of human immune interferon in response to staphylococcal enterotoxin A (SEA). Two patients showed a trend toward enhanced lymphocyte transformation to PHA while taking ibuprofen. In two patients who were studied 8–10 weeks after discontinuation of oral ketoconazole therapy, clinical recurrence of CMC was not prevented by oral ibuproten therapy.

UR - http://www.scopus.com/inward/record.url?scp=84980237689&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84980237689&partnerID=8YFLogxK

U2 - 10.1111/j.1365-4362.1985.tb05423.x

DO - 10.1111/j.1365-4362.1985.tb05423.x

M3 - Article

VL - 24

SP - 183

EP - 187

JO - International Journal of Dermatology

JF - International Journal of Dermatology

SN - 0011-9059

IS - 1

ER -